

Contents

Chapter I	General introduction to tumor immunology and scope of the thesis	9
-----------	--	---

Part A

25

Chapter II	Introduction to MHC class II in tumor immunology: prognostic marker and target for immune modulation <i>Immunobiology 2006;211:619-25</i>	27
------------	--	----

Chapter III	Class II-associated Invariant Chain peptide expression on myeloid leukemic blasts predict poor clinical outcome <i>Cancer Research 2004;64:5546-50</i>	39
-------------	---	----

Chapter IV	Down-modulation of Invariant Chain and CLIP expression enhances CD4+ T cell recognition of acute myeloid leukemic blasts <i>Submitted</i>	53
------------	--	----

Chapter V	Aberrant MHC class II antigen presentation is linked to expansion of the activated T cell compartment in B-CLL <i>Submitted</i>	73
-----------	--	----

Part B

91

Chapter VI	Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome <i>Haematologica 2009, in press</i>	93
------------	--	----

Chapter VII	High expression of decoy receptor TRAIL-R3 on AML blasts is associated with poor clinical outcome and induces apoptosis resistance which can be overcome by targeting TRAIL-R2 <i>Submitted</i>	113
-------------	--	-----

Chapter VIII	High <i>INDO</i> (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome <i>Haematologica 2008;93:1894-1898</i>	133
--------------	---	-----

Chapter IX	Conclusions, discussion and future perspectives	145
------------	---	-----

Appendices

Curriculum Vitae	159
List of publications	160
Nederlandse samenvatting voor de leek	163
Dankwoord	167
List of abbreviations	173

